Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CBT 101 - CHA Bio & Diostech

Next Previous
Drug Profile

CBT 101 - CHA Bio & Diostech

Alternative Names: CBT 101 - CHA Bio & Diostech; CHANK-101

Latest Information Update: 23 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CHA Bio & Diostech
  • Class Antineoplastics; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glioblastoma
  • Phase I Solid tumours
  • Clinical Phase Unknown Biliary cancer; Multiple myeloma; Triple negative breast cancer

Most Recent Events

  • 21 Sep 2026 Dong-A University Hospital plans a clinical trial for Glioblastoma (Second-line therapy orgreater, Recurrent, In the elderly, In adults) in South Korea (IV), in September 2026 (NCT07831161)
  • 31 Aug 2026 Clinical trials in Biliary cancer (Parenteral), prior to August 2026 (CHA Biotech pipeline, August 2026)
  • 31 Aug 2026 Clinical trials in Multiple myeloma (Parenteral), prior to August 2026 (CHA Biotech pipeline, August 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top